These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19549918)

  • 1. Active Notch1 confers a transformed phenotype to primary human melanocytes.
    Pinnix CC; Lee JT; Liu ZJ; McDaid R; Balint K; Beverly LJ; Brafford PA; Xiao M; Himes B; Zabierowski SE; Yashiro-Ohtani Y; Nathanson KL; Bengston A; Pollock PM; Weeraratna AT; Nickoloff BJ; Pear WS; Capobianco AJ; Herlyn M
    Cancer Res; 2009 Jul; 69(13):5312-20. PubMed ID: 19549918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of different morphologic features of malignant melanoma and pigmented lesions after transformation of murine melanocytes with bFGF-cDNA and H-ras, myc, neu, and E1a oncogenes.
    Ramon y Cajal S; Suster S; Halaban R; Filvaroff E; Dotto GP
    Am J Pathol; 1991 Feb; 138(2):349-58. PubMed ID: 1992762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression.
    Liu ZJ; Xiao M; Balint K; Smalley KS; Brafford P; Qiu R; Pinnix CC; Li X; Herlyn M
    Cancer Res; 2006 Apr; 66(8):4182-90. PubMed ID: 16618740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. V599EB-RAF is an oncogene in melanocytes.
    Wellbrock C; Ogilvie L; Hedley D; Karasarides M; Martin J; Niculescu-Duvaz D; Springer CJ; Marais R
    Cancer Res; 2004 Apr; 64(7):2338-42. PubMed ID: 15059882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.
    Yu H; McDaid R; Lee J; Possik P; Li L; Kumar SM; Elder DE; Van Belle P; Gimotty P; Guerra M; Hammond R; Nathanson KL; Dalla Palma M; Herlyn M; Xu X
    Am J Pathol; 2009 Jun; 174(6):2367-77. PubMed ID: 19389934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.
    Zhu G; Yi X; Haferkamp S; Hesbacher S; Li C; Goebeler M; Gao T; Houben R; Schrama D
    Cancer Lett; 2016 Jun; 376(1):43-52. PubMed ID: 27000992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.
    Cheung M; Sharma A; Madhunapantula SV; Robertson GP
    Cancer Res; 2008 May; 68(9):3429-39. PubMed ID: 18451171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma.
    Mueller DW; Rehli M; Bosserhoff AK
    J Invest Dermatol; 2009 Jul; 129(7):1740-51. PubMed ID: 19212343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation.
    Toricelli M; Melo FH; Peres GB; Silva DC; Jasiulionis MG
    Mol Cancer; 2013 Mar; 12():22. PubMed ID: 23522389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment.
    Seftor EA; Brown KM; Chin L; Kirschmann DA; Wheaton WW; Protopopov A; Feng B; Balagurunathan Y; Trent JM; Nickoloff BJ; Seftor RE; Hendrix MJ
    Cancer Res; 2005 Nov; 65(22):10164-9. PubMed ID: 16288000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synchronized Targeting of Notch and ERBB Signaling Suppresses Melanoma Tumor Growth through Inhibition of Notch1 and ERBB3.
    Zhang K; Wong P; Salvaggio C; Salhi A; Osman I; Bedogni B
    J Invest Dermatol; 2016 Feb; 136(2):464-472. PubMed ID: 26967479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated Notch1 expression is associated with angiogenesis in cutaneous melanoma.
    Murtas D; Piras F; Minerba L; Maxia C; Ferreli C; Demurtas P; Lai S; Mura E; Corrias M; Sirigu P; Perra MT
    Clin Exp Med; 2015 Aug; 15(3):351-60. PubMed ID: 25034654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanoma.
    Meier F; Caroli U; Satyamoorthy K; Schittek B; Bauer J; Berking C; Möller H; Maczey E; Rassner G; Herlyn M; Garbe C
    Exp Dermatol; 2003 Jun; 12(3):296-306. PubMed ID: 12823444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.
    Keller-Melchior R; Schmidt R; Piepkorn M
    J Invest Dermatol; 1998 Jun; 110(6):932-8. PubMed ID: 9620301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer.
    Bastian BC
    Oncogene; 2003 May; 22(20):3081-6. PubMed ID: 12789284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.
    Bhatt KV; Spofford LS; Aram G; McMullen M; Pumiglia K; Aplin AE
    Oncogene; 2005 May; 24(21):3459-71. PubMed ID: 15735667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression analysis after receptor tyrosine kinase activation reveals new potential melanoma proteins.
    Teutschbein J; Haydn JM; Samans B; Krause M; Eilers M; Schartl M; Meierjohann S
    BMC Cancer; 2010 Jul; 10():386. PubMed ID: 20663135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
    Goel VK; Ibrahim N; Jiang G; Singhal M; Fee S; Flotte T; Westmoreland S; Haluska FS; Hinds PW; Haluska FG
    Oncogene; 2009 Jun; 28(23):2289-98. PubMed ID: 19398955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses.
    Jiang L; Campagne C; Sundström E; Sousa P; Imran S; Seltenhammer M; Pielberg G; Olsson MJ; Egidy G; Andersson L; Golovko A
    BMC Cancer; 2014 Nov; 14():857. PubMed ID: 25413220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor progression in the human melanocytic system.
    Kath R; Rodeck U; Menssen HD; Mancianti ML; Linnenbach AJ; Elder DE; Herlyn M
    Anticancer Res; 1989; 9(4):865-72. PubMed ID: 2554787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.